The present invention provides a hydrogel platform using, as a substrate, hyaluronic acid (HA) conjugated to a pyrogallol (PG) moiety. The HA-PG conjugate of the present invention can be rapidly crosslinked by two different methods, in each of which an oxidizing agent is used or a pH is adjusted. The hydrogel of the present invention can not only have excellent biocompatibility, but also can have efficiently controlled physical characteristics such as a crosslinking rate, elasticity, and adhesive strength, depending on each crosslinking method. On the basis of such excellent stability and functionality, the hydrogel of the present invention can be used in various fields including drug delivery, biopharmaceutical materials such as a wound healing agent or anti-adhesive agent, medicines, and cosmetic products.

The present disclosure relates to synthesis of heparin, which may be bioequivalent to porcine USP Heparin Sodium. The synthesis may involve three intermediates starting from heparosan.

Disclosed is a method of preparing N-alkylated chitosan derivatives by treating chitosan with an acid and subsequently reacting the chitosan with an alkylating agent in the presence of a base. Also provided are novel N-alkylated chitosan derivatives.

A method of preparing a Senna obtusifolia seed extract rich in anthraquinones and a galactomannan extract includes the following steps: (1) crushing Senna obtusifolia seeds into a Senna obtusifolia seed powder; (2) extracting the Senna obtusifolia seed powder with 40-85% ethanol, filtering to obtain an extract solution and a residue; (3) concentrating the extract solution under vacuum to obtain a concentrated extract solution, spray-drying the concentrated extract solution to obtain the Senna obtusifolia seed extract; (4) extracting the residue with membrane filtered water, conducting a centrifugation to obtain a supernatant; (5) adding ammonium sulfate and ethanol to the supernatant to form a two-phase aqueous system, collecting a bottom layer of the two-phase aqueous system; and (6) conducting an ultrafiltration of the bottom layer with a cut-off molecular weight of 50 k-200 k to obtain a galactomannan extract solution, drying the galactomannan extract solution under vacuum to obtain the galactomannan extract.

The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.

The present invention relates to a process for the preparation of pharmaceutical, injectable or ophthalmic grade hyaluronic acid, or a salt thereof, for use in the dermocosmetic or pharmaceutical field or in medical devices, which comprises dissolution of hyaluronic acid or a salt thereof in organic solvent, a heat cycle, and recovery of the product by precipitation and successive washes in organic solvents.

A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.

Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty acid anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).

The present disclosure relates to: a chitosan-bilirubin conjugate; particles; and an oral pharmaceutical composition including same. The conjugate and/or particles according to the present disclosure have excellent antioxidant and anti-inflammatory effects, exhibit systemic inflammation relieving effects as well as intestinal inflammatory reaction relieving effects, and have the effect of normalizing the balance of intestinal microflora distribution, and thus, can be useful for treating inflammatory bowel diseases, systemic and chronic inflammatory diseases, etc.

The present invention is a process to produce Z-Chitosan to provide consistent and long-lasting antimicrobial, antiviral, antibacterial, antifungal, anti-spore, and anti-odor characteristics, the process comprises steps of preparing a liquid active agent comprising 50 ppm to 5,000 ppm aqueous solution of each of a Chitosan group, a herbal extract group, and a catalyst group using an emulsion crosslinking method for 24 to 144 hours at normal room conditions; preparing a powder form of the active agent by drying the liquid active agent; encapsulating the powder form of the active agent within a plastic, a polymer, a fabric to make a masterbatch of the product, and finally blending 1 to 10 percent of the masterbatch with a batch of plastic, polymer, or fabric to make an antimicrobial product, whereby the product shows antimicrobial and self-sanitizing efficacy for contact time between 2 hours to 24 hours and maintains its antimicrobial efficacy in the scale of years in different environment conditions.